Alpha-1 antitrypsin deficiency VX814 is an inherited disorder that may cause lung disease and liver disease. The signs and symptoms of the condition and the age at which they appear vary among individuals. People with alpha-1 antitrypsin deficiency usually develop the first signs and symptoms of lung disease between ages 20 and 50. Mutations in the SERPINA1 gene cause alpha-1 antitrypsin deficiency. This gene provides instructions for making a protein called alpha-1 antitrypsin, which protects the body from a powerful enzyme called neutrophil elastase. Without enough functional alpha-1 antitrypsin, neutrophil elastase destroys alveoli and causes lung disease. Abnormal alpha-1 antitrypsin can also accumulate in the liver and damage this organ. Environmental factors, such as exposure to tobacco smoke, chemicals, and dust, likely impact the severity of alpha-1 antitrypsin deficiency.
DelveInsight’s, “Alpha-1 antitrypsin deficiency -Pipeline Insights, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Alpha-1 antitrypsin deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Atopic Dermatitis Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Atopic Dermatitis (AD) market. A detailed picture of the Atopic Dermatitis (AD) pipeline landscape is provided, which includes the disease overview and Atopic Dermatitis (AD) treatment guidelines. The assessment part of the report embraces in-depth Atopic Dermatitis (AD) commercial assessment and clinical assessment of the Atopic Dermatitis (AD) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis (AD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
"Systemic Sclerosis associated Interstitial Lung Disease (SSc ILD) Pipeline Insights, 2021" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) market. A detailed picture of the Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) pipeline landscape is provided, which includes the disease overview and Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) treatment guidelines. The assessment part of the report embraces in-depth Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) commercial assessment and clinical assessment of the Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Comments
Post a Comment